Want to see HK:1681 full AI Analyst Report?
Top Page
Consun Pharmaceutical Group Ltd.
(1681)
Select Model
Select Model
Rating:82Outperform
Price Target:
HK$16.00
▼(-1.90% Downside)
Action:Reiterated
Date:08/28/26
The score is primarily supported by strong financial performance (high margins, strong ROE, and very low leverage) and an attractive valuation (low P/E and high dividend yield). This is partly offset by a mixed technical picture, with the stock still below longer-term moving averages and RSI near overbought, plus some uncertainty around the latest cash-conversion visibility.
Positive Factors
High, durable profitability
Sustained high gross and net margins indicate pricing strength, product differentiation and disciplined cost control. Maintaining these levels across several years provides a durable earnings base and supports reinvestment in specialty medicines.
Negative Factors
Uneven free-cash-flow growth
Although cumulative cash generation is strong, intermittent negative free cash flow shows that earnings do not convert smoothly into cash every year. This can constrain reinvestment and shareholder returns during periods of working-capital or investment needs.
Read all positive and negative factors
Positive Factors
Negative Factors
High, durable profitability
Sustained high gross and net margins indicate pricing strength, product differentiation and disciplined cost control. Maintaining these levels across several years provides a durable earnings base and supports reinvestment in specialty medicines.
Read all positive factors
Consun Pharmaceutical Group Ltd. (1681) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$10.82B
Dividend Yield5.98%
Average Volume (3M)1.77M
Price to Earnings (P/E)8.1
Beta (1Y)0.55
Revenue Growth15.05%
EPS Growth20.58%
CountryHK
Employees2,847
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.26
Shares Outstanding841,547,100
10 Day Avg. Volume1,933,453
30 Day Avg. Volume1,768,798
Financial Highlights & Ratios
PEG Ratio0.83
Price to Book (P/B)2.65
Price to Sales (P/S)3.52
P/FCF Ratio10.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$18.45Price Target Upside13.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)1.48
Revenue Forecast (FY)HK$3.87B
Consun Pharmaceutical Group Ltd. Business Overview & Revenue Model
Company Description
Consun Pharmaceutical Group Limited operates as an investment holding company, primarily engaged in the research, development, manufacturing, and distribution of traditional Chinese medicines and sophisticated medical contrast agents throughout th...
How the Company Makes Money
Consun Pharmaceutical Group primarily makes money by selling prescription pharmaceutical products in Mainland China. Its core revenue stream is product sales from its self-manufactured drug portfolio, with sales typically generated through (i) hos...
Consun Pharmaceutical Group Ltd. Financial Statement Overview
Summary
Income Statement
92
Very Positive
Balance Sheet
94
Very Positive
Cash Flow
78
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.42B | 2.97B | 2.59B | 2.34B | 2.04B |
| Gross Profit | 2.67B | 2.24B | 1.92B | 1.76B | 1.53B |
| EBITDA | 1.21B | 1.05B | 963.06M | 785.89M | 728.71M |
| Net Income | 1.08B | 910.46M | 784.53M | 682.91M | 590.17M |
Balance Sheet | |||||
| Total Assets | 6.41B | 5.85B | 5.51B | 4.89B | 4.36B |
| Cash, Cash Equivalents and Short-Term Investments | 3.95B | 3.87B | 3.58B | 3.04B | 2.43B |
| Total Debt | 213.01M | 267.17M | 511.53M | 460.18M | 610.97M |
| Total Liabilities | 1.56B | 1.46B | 1.59B | 1.45B | 1.45B |
| Stockholders Equity | 4.54B | 4.10B | 3.63B | 3.15B | 2.62B |
Cash Flow | |||||
| Free Cash Flow | 1.14B | 977.99M | 766.41M | 896.09M | 627.29M |
| Operating Cash Flow | 1.21B | 1.09B | 818.97M | 947.68M | 725.54M |
| Investing Cash Flow | -2.15B | -186.91M | -231.77M | -368.80M | -298.31M |
| Financing Cash Flow | -711.74M | -729.26M | -280.10M | -342.20M | -166.66M |
Consun Pharmaceutical Group Ltd. Technical Analysis
Negative
16.31
Price Trends
13.28
Negative
13.51
Negative
14.57
Negative
Market Momentum
-0.04
Positive
45.57
Neutral
17.92
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1681, the sentiment is Negative. The current price of 16.31 is above the 20-day moving average (MA) of 13.25, above the 50-day MA of 13.28, and above the 200-day MA of 14.57, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 45.57 is Neutral, neither overbought nor oversold. The STOCH value of 17.92 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1681.
Consun Pharmaceutical Group Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | HK$10.82B | 8.07 | 25.10% | 5.98% | 15.05% | 20.58% | |
59 Neutral | HK$15.26B | 67.91 | 1.67% | 3.93% | 3.10% | -46.64% | |
53 Neutral | HK$6.52B | -5.25 | -4.98% | 0.27% | -15.80% | -298.94% | |
52 Neutral | HK$8.78B | 41.36 | 4.10% | 3.17% | 4.81% | -48.21% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$6.90B | 18.41 | 5.03% | 1.51% | 29.68% | ― |
* Healthcare Sector Average
HK:1681
Consun Pharmaceutical Group Ltd.
13.04
-2.30
-14.99%
HK:0570
China Traditional Chinese Medicine Holdings Co
1.27
-0.94
-42.53%
HK:0460
Sihuan Pharmaceutical Holdings Group
0.72
-0.92
-56.04%
HK:9989
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
4.23
-1.44
-25.47%
HK:0719
Shandong Xinhua Pharmaceutical Company Limited Class H
5.44
-2.11
-27.96%
HK:2637
Fujian Haixi Pharmaceuticals Co., Ltd. Class H
193.00
88.80
85.22%
Consun Pharmaceutical Group Ltd. Corporate Events
Consun Pharmaceutical Declares Interim Cash Dividend for First Half of 2026
Aug 26, 2026
Consun Pharmaceutical Group Limited, a Hong Kong-listed pharmaceutical company focused on the development and distribution of medical products, maintains its primary listing under stock code 01681 and uses Computershare Hong Kong Investor Services...
Consun Pharmaceutical Delivers Strong Interim Earnings and Raises Payout
Aug 26, 2026
Consun Pharmaceutical Group reported robust interim results for the six months ended 30 June 2026, with revenue rising 13.8% year-on-year to RMB1.78 billion and gross profit reaching RMB1.45 billion. Profit attributable to equity shareholders grew...
Consun Pharmaceutical Schedules Board Meeting to Review 2026 Interim Results
Aug 10, 2026
Consun Pharmaceutical Group has scheduled a board meeting for 26 August 2026 to review and approve its unaudited consolidated interim results for the six months ended 30 June 2026. The board will also decide on the publication of these interim res...
Consun Pharmaceutical buys 30% stake in Shanghai Huamao to deepen biotech integration
Jun 8, 2026
Consun Pharmaceutical Group’s wholly owned unit Guangzhou Consun Pharmaceutical has agreed to invest RMB191.4 million for a 30% stake in Shanghai Huamao Pharmaceutical, a biotechnology and pharmaceutical company and existing supplier based i...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.